Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + busulfan + melphalan
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + busulfan + melphalan (Gem-Bu-Mel) is a high-dose chemotherapy conditioning regimen developed by the M.D. Anderson Cancer Center for patients with relapsed or refractory Hodgkin's disease (Hodgkin lymphoma) undergoing autologous hematopoietic stem cell transplantation (AHCT). The regimen utilizes the synergistic effects of gemcitabine, a nucleoside analog that inhibits DNA synthesis and repair, with the alkylating agents busulfan and melphalan. Gemcitabine is known to enhance the cytotoxicity of alkylators by inhibiting the repair of DNA interstrand cross-links. This combination is designed to provide intensive cytoreduction to overcome chemoresistance in heavily pretreated patients before they receive stem cell support.
- Other names
- Gemcitabine, Busulfan, and Melphalan conditioning regimenMD Anderson Gem-Bu-Mel protocol
02
Targets
DNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + busulfan + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + busulfan + melphalan.